Answer
Pertuzumab and trastuzumab bind distinct HER2 subdomains without competing and both mediate antibody-dependent cell-mediated cytotoxicity (ADCC), which in vitro preferentially targets HER2-overexpressing cancer cells over cells that do not overexpress HER2.
Sources for this answer
- Phesgo 600 mg/600 mg, 1200 mg/600 mg solution for injectionRoche Products Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 8Document updated
Sources checked